Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 10:11:1273-1280.
doi: 10.2147/OPTH.S118689. eCollection 2017.

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution

Daniel Lee  1 , Anand V Mantravadi  1 , Jonathan S Myers  1
Affiliations
Review

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution

Daniel Lee et al. Clin Ophthalmol. .

Abstract

Glaucoma is a leading cause of irreversible blindness worldwide. The reduction of intraocular pressure has been well established as an effective treatment to prevent both the development and the progression of all forms of glaucoma. Bimatoprost 0.03% ophthalmic solution, introduced in 2001, is a synthetic prostamide with the unique mechanism of improving both uveoscleral and trabecular outflow. Comparative studies with other pharmacotherapies have shown favorable results for bimatoprost as a potent ocular hypotensive agent that is generally well tolerated. Common side effects include conjunctival hyperemia, eyelash growth, iris pigmentation and periorbital changes. Hyperemia rates were reduced following the introduction of bimatoprost 0.01%. Bimatoprost should be used with caution in those with higher risk of developing ocular inflammation and macular edema. However, the perceived risk of bimatoprost in these patient populations is likely greater than the actual risk observed in practice. Bimatoprost is currently in the center of several clinical trials including its use for dermatologic applications and sustained-release therapies for the treatment of ocular hypertension and glaucoma.

Keywords: bimatoprost; glaucoma; ocular hypertension.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr Myers reported research grants to his institutions from Aerie, Allergan, Diopsys, Glaukos, Haag Streit, Heidelberg,Inotek Merck, Novartis, Valeant, and Zeiss. He has been a consultant for Aerie, Allergan Gore Medical, Inotek, and Novartis, and has spoken on behalf of Allergan and Novartis. Dr Mantravadi reported he has been a consultant for Allergan and Gore Medical. The authors report no other conflicts of interest in this work.

References

    1. Parrish RK, 2nd, Feuer WJ, Schiffman JC, Lichter PR, Musch DC, CIGTS Optic Disc Study Group Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. Am J Ophthalmol. 2009;147(4):717–724.e1. - PMC - PubMed
    1. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. Discussion 829–830. - PubMed
    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267. - PMC - PubMed
    1. Leske MC, Connell AM, Wu SY, Hyman L, Schachat AP. Distribution of intraocular pressure. The Barbados Eye Study. Arch Ophthalmol. 1997;115(8):1051–1057. - PubMed

LinkOut - more resources